In¯uence of the A 3 G (-3826) uncoupling protein-1 gene (UCP1) variant on the dynamics of body weight before and after gastroplasty in morbidly obese subjects
We have read with interest the recent paper by Gagnon et al, 1 who reported that the A-3826G mutation in the human uncoupling protein 1 (UCP1) gene is not associated with any of the obesity-related phenotypes or weight gain in the Swedish Obese Subjects cohorts. These results contrast with previous observations, also published in this Journal, showing that the A-3826G UCP1 gene variant was associated with: 1) higher weight gain during adult life in a study of 238 morbidly obese French individuals 2 ; 2) the susceptibility to gain body weight over 12 y of followup in a study of 261 subjects from the Quebec Family Study 3 ; and 3) a resistance to weight loss during a low calorie diet in 163 obese French patients. 4 We analysed the prevalence of the UCP1 gene variant in morbidly obese patients who were candidates for bariatric surgery at the University Hospital in Lie Áge, Belgium. We were particularly interested in studying the in¯uence of the UCP1 polymorphism on the history of obesity in that population and on the dynamics of weight loss after surgery.
Detection of the A 3 G UCP1 variant was carried out by polymerase chain reaction (PCR) ampli®cation of speci®c fragments and subsequent digestion with Bcl I.
5 Plasma leptin levels were determined by radioimmunoassay (RIA; Linco Research Inc., St Charles, MO). Statistical analysis was performed using Chisquare test and unpaired Student's t-test.
UCP1 polymorphism was analysed in 39 severely obese individuals, and the AA genotype was found in 31 subjects, whereas the AG genotype was detected in eight subjects, corresponding to a prevalence of 21% of this variant. No subject was found homozygotic (GG) for the mutation. No signi®cant differences were observed in obesity-related phenotypes in the two subgroups, except that the subjects with the AG genotype presented a signi®cantly higher prevalence of familial obesity among ®rst-degree relatives and an earlier onset of obesity (Table 1) . For example, 71% of the AG carriers developed obesity before the age of 12 y, in contrast to only 29% among the AA carriers (P 0.036). Consequently, the obesity duration at the time of clinical examination and the body weight at the age of 20 y were signi®cantly higher in the group of subjects with the AG genotype, compared to the non-carriers of the mutation. Weight gain between the age of 20 y and the time of the pre-surgery screening tended to be lower (and not higher as previously reported 2 ) in the former than in the latter group (not statistically signi®cant, NS).
Of this initial cohort, 27 patients, including seven with the AG genotype, were submitted to a gastroplasty and were followed for at least six months afterwards, but no signi®cant differences in weight loss were observed between the two subgroups (Table  1) . Mean plasma leptin levels were similar in the carriers and non-carriers of the UCP1 gene variant before surgery (39.0 AE 13.7 ngaml vs 43.3 AE 22.9 ngaml; NS), and decreased signi®cantly (P`0.001) and similarly after gastroplasty (20.1 AE 12.6 ngaml vs 24.6 AE 14.1 ngaml; NS). These leptin data suggest that fat mass was similar before surgery and decreased similarly after gastroplasty in the AG and AA subgroups.
The frequency of the A 3 G UCP1 polymorphism observed in this morbidly obese population (21%) was only slightly lower than that previously reported, 1±4,6 and our results con®rm those of Gagnon et al 1 showing that DNA polymorphism in the UCP1 gene had no effect on obesity-related phenotypes. More particularly, we did not see any difference in weight gain during the adult life, in contrast to what has been previously suggested.
2 However, we did observe differences in the history of obesity of the subjects with the A-3826G variant, who had signi®cantly more frequent obese ®rst-degree relatives and an earlier onset of obesity. This contrasts with a recent study in young healthy Caucasians that did not reveal any difference in body mass index (BMI) or weight gain during childhood or adolescence between carriers and non-carriers of the AG variant, 6 but it should be pointed out that these results were obtained in much leaner (averaged BMI 23 kgam 2 ) and younger (25 y) subjects. Finally, mean weight loss six months after gastroplasty was similar in the carriers and noncarriers of the AG variant. Thus, these results do not show a resistance to weight loss during energy deprivation, as previously reported in carriers during a low calorie diet.
In conclusion, our observations con®rm the results of Gagnon et al 1 who showed that the A 3 G UCP1 polymorphism does not play a major role in obesityrelated phenotypes. In addition, we have demonstrated that this genetic variant does not signi®cantly in¯u-ence the dynamics of weight loss after bariatric surgery. However, we have shown a possible association of the A-3826G UCP1 gene variant with a family history of obesity and early weight gain during childhood and adolescence. This new observation needs to be con®rmed in a larger series.
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